Evrofarma (Greece) Performance
| EVROF Stock | EUR 3.75 0.05 1.32% |
On a scale of 0 to 100, Evrofarma holds a performance score of 19. The firm shows a Beta (market volatility) of -0.13, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Evrofarma are expected to decrease at a much lower rate. During the bear market, Evrofarma is likely to outperform the market. Please check Evrofarma's treynor ratio, kurtosis, period momentum indicator, as well as the relationship between the downside variance and day median price , to make a quick decision on whether Evrofarma's price patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Evrofarma SA are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Evrofarma sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Price Earnings Ratio | 10.6329 | |
| Total Cashflows From Investing Activities | -3.3 M |
Evrofarma |
Evrofarma Relative Risk vs. Return Landscape
If you would invest 272.00 in Evrofarma SA on November 5, 2025 and sell it today you would earn a total of 103.00 from holding Evrofarma SA or generate 37.87% return on investment over 90 days. Evrofarma SA is generating 0.5736% of daily returns and assumes 2.393% volatility on return distribution over the 90 days horizon. Simply put, 21% of stocks are less volatile than Evrofarma, and 89% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Evrofarma Target Price Odds to finish over Current Price
The tendency of Evrofarma Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.75 | 90 days | 3.75 | about 14.77 |
Based on a normal probability distribution, the odds of Evrofarma to move above the current price in 90 days from now is about 14.77 (This Evrofarma SA probability density function shows the probability of Evrofarma Stock to fall within a particular range of prices over 90 days) .
Evrofarma Price Density |
| Price |
Predictive Modules for Evrofarma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Evrofarma SA. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Evrofarma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Evrofarma is not an exception. The market had few large corrections towards the Evrofarma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Evrofarma SA, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Evrofarma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.50 | |
β | Beta against Dow Jones | -0.13 | |
σ | Overall volatility | 0.43 | |
Ir | Information ratio | 0.19 |
Evrofarma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Evrofarma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Evrofarma SA can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Evrofarma SA has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the revenue of 38.81 M. Net Loss for the year was (355 K) with profit before overhead, payroll, taxes, and interest of 3.84 M. | |
| Evrofarma SA has accumulated about 554 K in cash with (805 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04. | |
| Roughly 76.0% of the company shares are held by company insiders |
Evrofarma Fundamentals Growth
Evrofarma Stock prices reflect investors' perceptions of the future prospects and financial health of Evrofarma, and Evrofarma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evrofarma Stock performance.
| Return On Equity | -0.0792 | |||
| Return On Asset | -0.0024 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (0) % | |||
| Current Valuation | 33.15 M | |||
| Shares Outstanding | 13.67 M | |||
| Price To Earning | 13.89 X | |||
| Price To Sales | 0.26 X | |||
| Revenue | 38.81 M | |||
| EBITDA | 1.28 M | |||
| Cash And Equivalents | 554 K | |||
| Cash Per Share | 0.04 X | |||
| Total Debt | 18.45 M | |||
| Debt To Equity | 158.30 % | |||
| Book Value Per Share | 0.92 X | |||
| Cash Flow From Operations | (805 K) | |||
| Earnings Per Share | 0.08 X | |||
| Total Asset | 44 M | |||
| Retained Earnings | (3 M) | |||
| Current Asset | 14 M | |||
| Current Liabilities | 13 M | |||
About Evrofarma Performance
By analyzing Evrofarma's fundamental ratios, stakeholders can gain valuable insights into Evrofarma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Evrofarma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Evrofarma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
It offers milk and liquids, ayran, cheese and organic cheese, and yogurt. EVROFARMA is traded on Athens Stock Exchange in Greece.Things to note about Evrofarma SA performance evaluation
Checking the ongoing alerts about Evrofarma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Evrofarma SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Evrofarma SA has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the revenue of 38.81 M. Net Loss for the year was (355 K) with profit before overhead, payroll, taxes, and interest of 3.84 M. | |
| Evrofarma SA has accumulated about 554 K in cash with (805 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04. | |
| Roughly 76.0% of the company shares are held by company insiders |
- Analyzing Evrofarma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evrofarma's stock is overvalued or undervalued compared to its peers.
- Examining Evrofarma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Evrofarma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evrofarma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Evrofarma's stock. These opinions can provide insight into Evrofarma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Evrofarma Stock analysis
When running Evrofarma's price analysis, check to measure Evrofarma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evrofarma is operating at the current time. Most of Evrofarma's value examination focuses on studying past and present price action to predict the probability of Evrofarma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evrofarma's price. Additionally, you may evaluate how the addition of Evrofarma to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |